Resonance Health (RHT.AX) Stock Price
Resonance Health Price
Revenue has compounded at 11.9% per year over the past 19 years to 15.75 M AUD. Earnings per share have grown at 3.8% per year over the last 17 years. Resonance Health's net margin stands at 9.6%, up from -29.8% several years earlier.
Resonance Health stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Resonance Health business model & stock analysis
Frequently asked questions about Resonance Health
The business model of Resonance Health Ltd focuses on providing innovative medical imaging software and services. The company aims to improve patient care and outcomes through its advanced technology solutions. Resonance Health specializes in the development and commercialization of non-invasive diagnostic tools, particularly in the field of liver and cardiac diseases. By leveraging its expertise in quantitative analysis and iron overload assessment, Resonance Health offers reliable and efficient solutions for diagnosing and managing various health conditions. The company operates by licensing its software to medical institutions and partnering with healthcare providers, ensuring widespread accessibility and utilization of its cutting-edge technologies.
Resonance Health Ltd is primarily active in the healthcare and medical technology industries.
The main competitors of Resonance Health Ltd in the market include other companies operating in the medical diagnostics and healthcare sector. Some prominent competitors are InHealth Group, Q BioMed, and Novartis AG. Resonance Health Ltd faces competition from these companies in developing innovative diagnostic solutions and providing high-quality healthcare services.
Resonance Health Ltd. is a leading provider of automated, non-invasive medical imaging software and analysis services. Founded in 1987, the company has a rich history of innovation and expertise in the field of liver and cardiac MRI imaging. Resonance Health's technology allows for accurate and reliable diagnosis of liver iron concentration and cardiac ejection fraction, essential measurements for monitoring patients with iron overload and heart conditions. With a strong commitment to research and development, Resonance Health continues to develop cutting-edge solutions that improve patient outcomes and streamline healthcare processes. As a trusted name in the industry, Resonance Health Ltd. has gained recognition globally for its advanced medical imaging products and services.
Resonance Health Ltd, a leading company in the healthcare sector, has accomplished several significant milestones. One noteworthy achievement is the development of FerriScan®, an advanced diagnostic tool for measuring liver iron concentration. Through extensive research and innovative technology, Resonance Health Ltd has revolutionized the diagnosis and monitoring of iron overload disorders such as hereditary hemochromatosis and thalassemia. The company has also expanded its global presence by establishing partnerships with renowned medical institutions and securing regulatory approvals for its groundbreaking products. With a relentless commitment to advancing patient care, Resonance Health Ltd continues to make remarkable strides in the field of medical diagnostics.
Resonance Health Ltd is primarily present in multiple countries and regions across the world. With its global reach, the company has established a strong presence in key markets. Its operations span across Australia, the United States, Europe, and Asia-Pacific regions. Resonance Health Ltd's commitment to expanding its footprint internationally has enabled it to serve a diverse range of customers and collaborate with partners on a global scale. This global presence reinforces Resonance Health Ltd's position as a leading player in the industry while allowing it to leverage various market opportunities and better serve its stakeholders.
Resonance Health Ltd represents values of innovation, excellence, and integrity in its corporate philosophy. As a leading stock health company, Resonance Health Ltd focuses on utilizing advanced technology and research to improve the diagnosis and treatment of liver diseases and iron disorders. With a dedicated team of experts, the company prioritizes accuracy and efficiency in its solutions, delivering reliable results to healthcare professionals worldwide. Resonance Health Ltd strives to enhance patient care by providing precise diagnostic tools, earning recognition for its commitment to quality and advancing medical knowledge.
Converted at the current exchange rate, the Resonance Health share trades at 0.05 EUR (0.08 AUD).
The Resonance Health share (RHT.AX) is listed on 1 stock exchanges, including: ASX (RHT.AX).
Resonance Health Ltd is a medical technology and software company specializing in the development and marketing of medical imaging devices, software, and services. The company is based in Perth, Australia, and operates worldwide.
The revenue of Resonance Health is 15.75 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Resonance Health is 1.51 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Resonance Health is currently 23.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Resonance Health stock.
The price-to-sales ratio (P/S) of Resonance Health is currently 2.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Resonance Health stock.
The Eulerpool Quality Score for Resonance Health is 6/10.
The ISIN of Resonance Health is AU000000RHT2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Resonance Health is A0BK8V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Resonance Health is RHT.AX. The ticker symbol is used to trade Resonance Health shares on the stock exchange.
Resonance Health stock
Resonance Health Peer Group
Resonance Health Ticker
Resonance Health FIGI
All fundamentals and in-depth analysis of Resonance Health
Our stock analysis for Resonance Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resonance Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.